Abstract
Background: Cardio-cerebral-vascular diseases, including myocardial infarction, atherosclerosis, hypertension, and stroke etc, are the major reasons for morbidity and mortality all over the world. Recent studies showed that inflammation exerts an important impact on the pathogenesis and development of cardio-cerebral-vascular diseases. “The cholinergic anti-inflammatory pathway”, mainly modulated through α7 nicotinic acetylcholine receptor (α7nAChR), has attracted much attention.
Objective: The purpose of this review was to discuss the role of α7nAChR during the pathological processes in myocardial infarction, atherosclerosis, hypertension and stroke.
Results: Most of the existing literatures involved in studying on myocardial infarction, atherosclerosis, hypertension and stroke showed that activation of α7nAChR might be a potential strategy for the prevention and treatment of these diseases.
Conclusion: Targeting α7nAChR to combat inflammation might be a novel therapy in cardiocerebral- vascular diseases.
Keywords: α7nAChR, inflammation, anti-inflammation target, cardio-cerebral-vascular diseases, myocardial infarction, hypertension.
Graphical Abstract
Current Drug Targets
Title:Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Volume: 18 Issue: 15
Author(s): Hui Fu, Min Ni, Ji-Kuai Chen, Ting Zhao, Ya-Ping Deng, Dong-Jie Li, Guo-Jun Jiang*Fu-Ming Shen*
Affiliation:
- Department of Pharmacy, Zhejiang Xiaoshan Hospital, 728 Yucaibei Road, Hangzhou, Zhejiang 311202,China
- Department of Pharmacy, Shanghai Tenth People's Hospital, Tongji University, 301 Middle Yanchang Road, Shanghai 200072,China
Keywords: α7nAChR, inflammation, anti-inflammation target, cardio-cerebral-vascular diseases, myocardial infarction, hypertension.
Abstract: Background: Cardio-cerebral-vascular diseases, including myocardial infarction, atherosclerosis, hypertension, and stroke etc, are the major reasons for morbidity and mortality all over the world. Recent studies showed that inflammation exerts an important impact on the pathogenesis and development of cardio-cerebral-vascular diseases. “The cholinergic anti-inflammatory pathway”, mainly modulated through α7 nicotinic acetylcholine receptor (α7nAChR), has attracted much attention.
Objective: The purpose of this review was to discuss the role of α7nAChR during the pathological processes in myocardial infarction, atherosclerosis, hypertension and stroke.
Results: Most of the existing literatures involved in studying on myocardial infarction, atherosclerosis, hypertension and stroke showed that activation of α7nAChR might be a potential strategy for the prevention and treatment of these diseases.
Conclusion: Targeting α7nAChR to combat inflammation might be a novel therapy in cardiocerebral- vascular diseases.
Export Options
About this article
Cite this article as:
Fu Hui, Ni Min, Chen Ji-Kuai, Zhao Ting, Deng Ya-Ping, Li Dong-Jie, Jiang Guo-Jun*, Shen Fu-Ming*, Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450116666150825123247
DOI https://dx.doi.org/10.2174/1389450116666150825123247 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Combination Therapy in Fibromyalgia
Current Pharmaceutical Design Adrenal Hyperandrogenism and Polycystic Ovary Syndrome
Current Pharmaceutical Design Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Clinical Research on the Aortic Elasticity in Patients with Type 1 Diabetes Mellitus Complicated with Hypertension
Current Medical Imaging Editorial from Editor-in-Chief (Thrombolytic and Catheter-Directed Therapy for Pulmonary Embolism: The Paradox of Clinical Outcomes and Theory)
Current Respiratory Medicine Reviews Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial(Current and Future Options for Lipid-lowering Therapy Beyond Statins)
Current Pharmaceutical Design Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews Methotrexate-Induced Pneumonitis: Heterogeneity of Bronchoalveolar Lavage and Differences between Cancer and Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Platelet Function Testing in Atherothrombotic Disease
Current Pharmaceutical Design Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research Nitric Oxide-Dependent Neovascularization Role in the Lower Extremity Disease
Current Pharmaceutical Design Advances in Antiplatelet Therapy for Stroke Prevention: the New P2Y12 antagonists
Current Drug Targets How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design Beta-Blockers as First Line Treatment of Hypertension: A Proponents View
Current Hypertension Reviews Molecular Targets for Promoting Wound Healing in Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Cardiac Gene Therapy: Therapeutic Potential and Current Progress
Current Gene Therapy High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design